GEP-NETs
Advertisement
A blood-based, non-invasive classifier can serve as an optional tool for conventional methods in the detection of NETs.
Cabozantinib continues to demonstrate significant improvement in PFS in extra-pancreatic or pancreatic neuroendocrine tumors.
Cabozantinib can be used for patients with pNETs or epNETs.
While GEP-NETs are often torpid, the incidence of patients with GEP-NETs has increased over the last few years.
First-line 177Lu-Dotatate with octreotide LAR can extend median PFS by 14 months in patients with advanced GEP-NETs.
A phase 1/2 study highlights the “extremely robust efficacy and good safety profile” of an anti–PD-L1 for EP-NEC.
Researchers can quantify absorbed doses through serial postinfusion scintigraphy measurements of the γ-emissions.
This marks the first FDA approval of a radioactive drug for patients 12 years or older with SSTER-positive GEP-NETs.
Researchers also found statistical significance for the TBR SULpeak of the primary and liver lesions.
Dr. Christopher Lieu gives an overview of the BESPOKE trial and the GALAXY arm of CIRCULATE-Japan, as well as NETTER-2.
PREF-NET was the first study to investigate patients’ preference of LAN administration setting in England and Wales.
For patients with NETs, somatostatin receptors are often targeted for nuclear theranostics applications.
Investigators compared the benefits of a nomogram with the AJCC staging system in predicting overall survival.
NETTER-2 is the first randomized study to demonstrate the efficacy of RLT as a 1L treatment for any form of cancer.
Physicians currently have a limited understanding of how to properly diagnose and treat type 1 gastric NETs.
Researchers analyzed cabozantinib's ability to improve the progression-free survival rate for patients.
A study found key tumor heterogeneities, including Ki-67 indices, might contribute to disease progression in GEP-NETs.
Lu-177-dotatate in PRRT appeared to treat GEP-NETs, though prior internal radiation may impede responses or worsen survival.
Researchers identified a circRNA signature as a potential biomarker for GEP-NETs.
Patients with advanced stage gastroenteropancreatic neuroendocrine tumors appear to benefit from PRRT.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.